Structural differences among cost–effectiveness models of human papillomavirus vaccines

References

• Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J. Clin. Virol.32(Suppl. 1), S1–S6 (2005).
   Google Scholar
• Gillison ML, Shah KV. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J. Natl Cancer Inst. Monogr. (31), 57–65 (2003).
   Google Scholar
• Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J. Natl Cancer Inst. Monogr.31, 14–19 (2003).
   PubMedGoogle Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol. Oncol.107(2 Suppl.), S19–S23 (2007).
   PubMed Web of Science ®Google Scholar
• Cox JT. Epidemiology and natural history of HPV. J. Fam. Pract. (Suppl.), 3–9 (2006).
   Google Scholar
• Pou AM, Rimell FL, Jordan JA et al. Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. Ann. Otol. Rhinol. Laryngol.104(10 Pt 1), 758–762 (1995).
   PubMed Web of Science ®Google Scholar
• Rimell FL, Shoemaker DL, Pou AM, Jordan JA, Post JC, Ehrlich GD. Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors. Laryngoscope107(7), 915–918 (1997).
   PubMed Web of Science ®Google Scholar
• Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J. Clin. Microbiol.37(10), 3316–3322 (1999).
   PubMed Web of Science ®Google Scholar
• Greer CE, Wheeler CM, Ladner MB et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J. Clin. Microbiol.33(8), 2058–2063 (1995).
   PubMed Web of Science ®Google Scholar
• Handsfield HH. Clinical presentation and natural course of anogenital warts. Am. J. Med.102(5A), 16–20 (1997).
   PubMedGoogle Scholar
• Boot HJ, Wallenburg I, de Melker HE et al. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine25(33), 6245–6256 (2007).
   PubMed Web of Science ®Google Scholar
• Brisson M, Van d, V, De Wals P, Boily MC. The potential cost–effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine25(29), 5399–5408 (2007).
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis.13(1), 28–41 (2007).
   PubMed Web of Science ®Google Scholar
• Ginsberg GM, Fisher M, Ben Shahar I, Bornstein J. Cost–utility analysis of vaccination against HPV in Israel. Vaccine25(37–38), 6677–6691 (2007).
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Kohli M, Grima D et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl Cancer Inst.96(8), 604–615 (2004).
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Kim JJ, Kobus K et al. Cost–effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine25(33), 6257–6270 (2007).
   PubMed Web of Science ®Google Scholar
• Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost–effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine26(1), 128–139 (2007).
   PubMed Web of Science ®Google Scholar
• Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost–effectiveness analysis in a low-resource setting. Br. J. Cancer97(9), 1322–1328 (2007).
   PubMed Web of Science ®Google Scholar
• Kulasingam S, Connelly L, Conway E et al. A cost–effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex. Health4(3), 165–175 (2007).
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA290(6), 781–789 (2003).
   PubMed Web of Science ®Google Scholar
• Sanders GD, Taira AV. Cost–effectiveness of a potential vaccine for human papillomavirus. Emerg. Infect. Dis.9(1), 37–48 (2003).
   PubMed Web of Science ®Google Scholar
• Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis.10(11), 1915–1923 (2004).
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.56(RR-2), 1–24 (2007).
   PubMedGoogle Scholar
• Barnabas RV, Kulasingam SL. Economic evaluations of human papillomavirus vaccines. Expert Rev. Pharmacoeconomics Outcomes Res.7(3), 251–267 (2007).
   PubMedGoogle Scholar
• Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol. Rev.28, 88–100 (2006).
   PubMed Web of Science ®Google Scholar
• Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine24(Suppl. 3), S178–S186 (2006).
   Web of Science ®Google Scholar
• Newall AT, Beutels P, Wood JG, Edmunds WJ, Macintyre CR. Cost–effectiveness analyses of human papillomavirus vaccination. Lancet Infect. Dis.7(4), 289–296 (2007).
   PubMed Web of Science ®Google Scholar
• Arnold RJ. Cost–effectiveness analysis: should it be required for drug registration and beyond? Drug Discov. Today12(21–22), 960–965 (2007).
   Google Scholar
• Institute of Medicine. Vaccines for the 21st Century: a Tool for Decision Making. National Academy Press, Washington, DC, USA (1999).
   Google Scholar
• Clifford GM, Gallus S, Herrero R et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet366(9490), 991–998 (2005).
   PubMed Web of Science ®Google Scholar
• Berkhof J, de Bruijne MC, Zielinski GD, Meijer CJ. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in The Netherlands. Int. J. Cancer115(2), 268–275 (2005).
   PubMedGoogle Scholar
• Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am. J. Epidemiol.165(7), 762–775 (2007).
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med.356(19), 1928–1943 (2007).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet369(9580), 2161–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine24(Suppl. 3), S35–S41 (2006).
   Web of Science ®Google Scholar
• Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal and vulvar pre-cancers and cancers in the United States. Cancer Epidemiol. Biomarkers Prev.17(7), 611–622 (2008).
   Google Scholar
• Carter JJ, Madeleine MM, Shera K et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res.61(5), 1934–1940 (2001).
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomarkers Prev.14(2), 467–475 (2005).
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer111(2), 278–285 (2004).
   PubMed Web of Science ®Google Scholar
• Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg.126(8), 935–939 (2000).
   PubMed Web of Science ®Google Scholar
• Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch. Otolaryngol. Head Neck Surg.121(12), 1386–1391 (1995).
   PubMed Web of Science ®Google Scholar
• Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics23(11), 1107–1122 (2005).
   PubMedGoogle Scholar
• Einstein MH. Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. Cancer Immunol. Immunother.57(4), 443–451 (2008).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer95(11), 1459–1466 (2006).
   PubMed Web of Science ®Google Scholar
• Villa LL, Ault KA, Giuliano AR et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine24(27–28), 5571–5583 (2006).
   PubMed Web of Science ®Google Scholar
• Viscidi RP, Schiffman M, Hildesheim A et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol. Biomarkers Prev.13(2), 324–327 (2004).
   PubMed Web of Science ®Google Scholar
• Viscidi RP, Snyder B, Cu-Uvin S et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol. Biomarkers Prev.14(1), 283–288 (2005).
   PubMed Web of Science ®Google Scholar
• Ghim S, Newsome J, Bell J, Sundberg JP, Schlegel R, Jenson AB. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp. Mol. Pathol.68(3), 147–151 (2000).
   PubMed Web of Science ®Google Scholar
• Munoz N, Mendez F, Posso H et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J. Infect. Dis.190(12), 2077–2087 (2004).
   PubMed Web of Science ®Google Scholar
• Trottier H, Mahmud S, Prado JC et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J. Infect. Dis.197(10), 1436–1447 (2008).
   PubMed Web of Science ®Google Scholar
• Konno R, Paez C, Sato S, Yajima A, Fukao A. HPV, histologic grade and age. Risk factors for the progression of cervical intraepithelial neoplasia. J. Reprod. Med.43(7), 561–566 (1998).
   Google Scholar
• Aspinall R. Age-related changes in the function of T cells. Microsc. Res. Tech.62(6), 508–513 (2003).
   PubMed Web of Science ®Google Scholar
• Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am. J. Obstet. Gynecol.191(1), 105–113 (2004).
   PubMed Web of Science ®Google Scholar
• Adam E, Berkova Z, Daxnerova Z, Icenogle J, Reeves WC, Kaufman RH. Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease. Am. J. Obstet. Gynecol.182(2), 257–264 (2000).
   PubMed Web of Science ®Google Scholar
• Dunne EF, Unger ER, Sternberg M et al. Prevalence of HPV infection among females in the United States. JAMA297(8), 813–819 (2007).
   PubMed Web of Science ®Google Scholar
• Lagro-Janssen T, Schijf C. What do women think about abnormal smear test results? A qualitative interview study. J. Psychosom. Obstet. Gynaecol.26(2), 141–145 (2005).
   PubMed Web of Science ®Google Scholar
• Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med. Decis. Making27(4), 414–422 (2007).
   PubMed Web of Science ®Google Scholar
• Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ328(7451), 1293 (2004).
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost–Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
   Google Scholar
• Insinga RP, Glass AG, Rush BB. Pap screening in a U.S. health plan. Cancer Epidemiol. Biomarkers Prev.13(3), 355–360 (2004).
   PubMed Web of Science ®Google Scholar
• Pinto AP, Guedes GB, Tuon FF, Maia HF, Collaco LM. Cervical cancer screening program of Parana: cytohistological correlation results after five years. Diagn. Cytopathol.33(4), 279–283 (2005).
   Google Scholar
• Zeferino LC, Pinotti JA, Jorge JP, Westin MC, Tambascia JK, Montemor EB. Organization of cervical cancer screening in Campinas and surrounding region, Sao Paulo State, Brazil. Cad. Saude Publica22(9), 1909–1914 (2006).
   Google Scholar
• Rebolj M, van Ballegooijen M, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in The Netherlands. Int. J. Cancer120(4), 806–812 (2007).
   PubMed Web of Science ®Google Scholar
• Janerich DT, Hadjimichael O, Schwartz PE et al. The screening histories of women with invasive cervical cancer, Connecticut. Am. J. Public Health85(6), 791–794 (1995).
   PubMedGoogle Scholar
• Chattopadhyay SK, Ebrahim SH, Tao G, McKenna MT. Use of cervical cancer screening among insured women: the extent of missed opportunities. Health Policy73(2), 194–201 (2005).
   Google Scholar
• Insinga RP, Glass AG, Rush BB. Response to “Use of cervical cancer screening among insured women: the extent of missed opportunities” [Health Policy 73, 194–201 (2005)]. Health Policy77(3), 245–246 (2006).
   Google Scholar
• Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control8(5), 755–763 (1997).
   PubMed Web of Science ®Google Scholar
• Adams EK, Breen N, Joski PJ. Impact of the National Breast and Cervical Cancer Early Detection Program on mammography and Pap test utilization among white, Hispanic, and African American women: Cancer109(Suppl. 2), 348–358 (2007).
   PubMedGoogle Scholar
• von Zuben MV, Derchain SF, Sarian LO, Westin MC, Thuler LC, Zeferino LC. The impact of a community intervention to improve cervical cancer screening uptake in the Amazon region of Brazil. Sao Paulo Med. J.125(1), 42–45 (2007).
   Google Scholar
• Sasieni P, Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. BMJ318(7193), 1244–1245 (1999).
   PubMed Web of Science ®Google Scholar
• Wang PD, Lin RS. Age-period-cohort analysis of cervical cancer mortality in Taiwan, 1974–1992. Acta Obstet. Gynecol. Scand.76(7), 697–702 (1997).
   Web of Science ®Google Scholar
• SEER*Stat 6.3.5 – SEER cancer incidence limited-use database, 1973–2004 and associated populations in binary format for Use by SEER*Stat. 4–16–2007. Cancer Statistics Branch, National Cancer Institute, National Insititutes of Health, Bethesda, MD, USA (2007).
   Google Scholar
• Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int. J. Cancer75(4), 536–545 (1998).
   PubMed Web of Science ®Google Scholar
• Vizcaino AP, Moreno V, Bosch FX et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int. J. Cancer86(3), 429–435 (2000).
   PubMed Web of Science ®Google Scholar
• Menczer J. The low incidence of cervical cancer in Jewish women: has the puzzle finally been solved? Isr. Med. Assoc. J.5(2), 120–123 (2003).
   Google Scholar
• Brown D; FUTURE II Study Group. HPV type 6/11/16/18 vaccine: first analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007 (Abstract G-1720b).
   Google Scholar
• Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet. Gynecol. Surv.61(6 Suppl. 1), S3–S14 (2006).
   PubMedGoogle Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367(9518), 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Fraser C, Tomassini JE, Xi L et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine25(21), 4321–4333 (2007).
   Google Scholar
• Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer121(3), 621–632 (2007).
   PubMed Web of Science ®Google Scholar
• Brown JB, Palmer AJ, Bisgaard P, Chan W, Pedula K, Russell A. The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res. Clin. Pract.50(Suppl. 3), S57–S64 (2000).
   Google Scholar